Eli Lilly stock trades down to $1,143 as FDA approves new eczema dosing, Eli Lilly and Company

Traders Union
All News
Companies
Eli Lilly down 0.49% today

Highlights

LLY is in a strong bullish trend, trading well above key moving averages across all timeframes.
Momentum indicators remain firmly positive, though some oscillators show overbought conditions and potential short-term exhaustion.
Price is expected to consolidate between $1,140 and $1,170, with a high probability of further upside unless support at $1,140 fails.

Bullish trends persist as price stays above key averages

LLY trades at $1,143.53, well above the MA-20 ($1,064.59), MA-50 ($983.08), and MA-200 ($951.91), confirming strong bullish trends across short, medium, and long-term timeframes. The Ichimoku Kijun on D1 is at $1,062.99, now serving as immediate support, while $1,064.59 (near-term support) and $983.08 (key support) underpin the structure; near-term resistance is seen at $1,148.22 (HMA D1 cluster), with key resistance at $1,182.73 (weekly high and also the 52-week high).

Mixed oscillator signals emerge amid strong momentum and buyer dominance

Momentum signals remain firmly positive: MACD and ADX on D1 both signal "Buy," highlighting clear upward pressure, though oscillators offer a different story. RSI on D1, at 68.34, remains just below the overbought threshold, while CCI and BBP are firmly overbought, and Stoch RSI gives a "Sell" indication, flagging short-term exhaustion. BBP confirms buyers have dominated, but some oscillators present a clear divergence from the strong trend. LLY is trading at $1,143.53, up from last week's close of $1,120.05, for a weekly gain of 2.10%. The price is positioned in the upper part of this week's range, with notable volatility at 12.27%. The week reflects robust buyer activity and a steady recovery from prior lows.

Upside favored as momentum remains robust but consolidation expected

Looking ahead, the projected trading range for the next week is $1,140 to $1,170, just beneath the record high of $1,182.73 and well above the 52-week low of $624.40. Based on W1 RSI, ADX, MACD, and MA-50 (all signaling "Buy"), there is a very high probability (more than 80%) of further upside, with a decline seen as much less likely. The baseline scenario anticipates consolidation within $1,140–$1,170. A breakout above $1,170 would open the path toward fresh highs near $1,182. A bearish turn below $1,140 could trigger profit taking toward the $1,064–$1,065 support band, but upward momentum remains dominant.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Eli Lilly maintained a bullish technical outlook, supported by strong momentum and positive clinical developments. Building on that foundation, the current article highlights how sustained support remains a critical factor, and investors should closely monitor whether these levels continue to hold as the prevailing scenario unfolds.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.